ISDA

Entry Detail

PDB ID:

8F0I

Keywords:

VIRAL PROTEIN/IMMUNE SYSTEM

Title:

Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody COVA309-22

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2, Homo sapiens

Host Organism:

Trichoplusia ni

PDB Version:

Deposition Date:

2022-11-03

Release Date:

2023-09-13

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.70 Å

R-Value Free:

0.27

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Spike protein S1
Chain IDs:A, D (auth: B), G
Chain Length:205
Number of Molecules:3
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Polymer Type:polypeptide(L)
Description:COVA309-22 heavy chain
Chain IDs:B (auth: C), E, H
Chain Length:223
Number of Molecules:3
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:COVA309-22 light chain
Chain IDs:C (auth: D), F, I
Chain Length:216
Number of Molecules:3
Biological Source:Homo sapiens

Ligand Molecules

NAG

Primary Citation

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.

Guerra, D, Beaumont, T, Radic, L, Kerster, G, van der Straten, K, Yuan, M, Torres, J.L, Lee, W.H, Liu, H, Poniman, M, Bontjer, I, Burger, J.A, Claireaux, M, Caniels, T.G, Snitselaar, J.L, Bijl, T.P.L, Kruijer, S, Ozorowski, G, Gideonse, D, Sliepen, K, Ward, A.B, Eggink, D, de Bree, G.J, Wilson, I.A, Sanders, R.W, van Gils, M.J, Guerra, D, Beaumont, T, Radic, L, Kerster, G, van der Straten, K, Yuan, M, Torres, J, Lee, W.H, Liu, H, Poniman, M, Bontjer, I, Burger, J.A, Claireaux, M, Caniels, T.G, Snitselaar, J.L, Bijl, T.P.L, Kruijer, S, Ozorowski, G, Gideonse, D, Sliepen, K, Ward, A.B, Eggink, D, de Bree, G.J, Wilson, I.A, Sanders, R.W, van Gils, M.J.Show

Iscience 26 108009 108009 (2023)

PMID: 37841584 DOI: 10.1016/j.isci.2023.108009

Abstact

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has remained a medical threat due to the evolution of multiple variants that acquire resistance to vaccines and prior infection. Therefore, it is imperative to discover monoclonal antibodies (mAbs) that neutralize a broad range of SARS-CoV-2 variants. A stabilized spike glycoprotein was used to enrich antigen-specific B cells from an individual with a primary Gamma variant infection. Five mAbs selected from those B cells showed considerable neutralizing potency against multiple variants, with COVA309-35 being the most potent against the autologous virus, as well as Omicron BA.1 and BA.2, and COVA309-22 having binding and neutralization activity against Omicron BA.4/5, BQ.1.1, and XBB.1. When combining the COVA309 mAbs as cocktails or bispecific antibodies, the breadth and potency were improved. In addition, the mechanism of cross-neutralization of the COVA309 mAbs was elucidated by structural analysis. Altogether these data indicate that a Gamma-infected individual can develop broadly neutralizing antibodies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures